Pancreatic Cancer: Key Takeaways from Cantor's 2nd Annual Oncology Symposium

Research evidence excerpt

Pancreatic Cancer: Key Takeaways from Cantor's 2nd Annual Oncology Symposium

Biotechnology

EQUITY RESEARCH Industry Report

May 26, 2026

Pancreatic Cancer: Key Takeaways from Cantor's 2nd

Research Analysts: Annual Oncology Symposium

Eric Schmidt

212-294-7724

Eric.Schmidt@cantor.com Pancreatic cancer is (finally!) having its day in the sun, and the excitement

Alexa Deemer Conzola, MD at our Oncology Day panel was quite palpable. We had the privilege of

212-610-2242 welcoming two expert GI medical oncologists, each with extensive clinical

Alexa.Deemer@cantor.com experience and deep insight into the rapidly changing pancreatic ductal

Imogen Mansfield adenocarcinoma (PDAC) landscape. 929-545-6495

Imogen.Mansfield@cantor.com

Li Watsek ●The primary focus of discussion centered on the emergence of Ras

212-915-1221 inhibitors in the metastatic setting. While both KOLs agreed that pan-

Li.Watsek@cantor.com Ras inhibitors will soon become the standard of care in the 2L+ setting,

there were conflicting views about the likelihood of success in 1L PDAC.

This was a very lively panel with some non-consensus views. Keep

reading below to learn more!

Move Over Chemo, It's Time For Ras Inhibitors To Shine...

●The KOLs noted that although chemotherapy is the backbone of

treatment in the metastatic setting today, they expect the landscape

to shift meaningfully as Ras inhibitors penetrate the market in the not-

so-distant future.

●In the 2L+ setting, the discussion focused on the recent top-

line OS data from RevMed's (NC) RASolute-302 study evaluating

pan-Ras inhibitor, daraxonrasib, against chemotherapy. The study

demonstrated unprecedented results, showing an approximate

doubling in overall survival relative to chemotherapy.

●Additional efficacy data (PFS, ORR) will be presented at ASCO.